Abhinav Garg

Director

In an era where healthcare solutions are evolving rapidly and the pharmaceutical industry is witnessing unprecedented growth, India's role as a global leader in medicine manufacturing is becoming increasingly prominent. With a reputation for delivering high-quality, patent-free products, the Indian pharmaceutical sector is favored worldwide, particularly by Middle Asian and Central Asian countries. Chandigarh-based Arvincare Healthcare, a key player in this thriving industry, exemplifies the excellence and innovation that set Indian manufacturers apart.

Epitomizing the spirit of Make in India with its robust growth and unwavering commitment to quality, Arvincare has evolved from humble beginnings in 2005 to a turnover of over 300 crores and a valuation of around 700 crores. Starting with generic domestic supply and now serving diverse sectors including government and defense, the company operates across 11 countries, with plans to expand across the globe.

“We attribute this growth to our unwavering consistency in manufacturing and packaging, which is crucial in the pharmaceutical industry. Even our longterm customers frequently emphasize our consistency in product quality, packaging, finishing, and efficacy”, states Arvind [designation]. “We ensure that our manufacturing processes always produce the same high-quality products, maintaining uniformity even after 10 years or more, with our proprietary recipe as the cornerstone.”

Maintaining stringent quality control measures, the company validates each product at three critical stages of production–raw materials, process, and finished goods. This commitment ensures that every product, whether a paracetamol tablet or a life-saving cancer medication, meets rigorous standards upheld by 750 USFDA-approved and 400 EUGMP-certified manufacturing facilities in India.

The company is at the forefront of innovation with groundbreaking technologies aimed at enhancing product security and efficiency. “Our dynamic barcoding system and no-gum label technology have revolutionized packaging, ensuring authenticity and mitigating risks of counterfeit medicines”, notes Arvind proudly, underscoring the company’s dedication to safeguarding consumer health globally. “We're also the only supplier in India for certain products due to these advanced technologies.”

A unique aspect of Arvincare's business model is its dual focus on contract manufacturing and the development of proprietary products. “There is a clear distinction between the two, but sometimes we get a clash”, acknowledges Arvind. To navigate this complexity, the company has implemented a semi-pricing model that bridges the gap between the two segments, ensuring that clients benefit from fair pricing without feeling the pinch of higher costs associated with proprietary products.

Central to Arvincare's success is its client-centric philosophy, prioritizing customer satisfaction through personalized service and flexible pricing to maintain enduring partnerships built on trust and reliability. The company proactively engages with clients and offers them its unwavering support through thick and thin.

Acknowledging the dynamic nature of pharmaceutical regulations, Arvincare adopts a cautious yet progressive approach. Believing in steady growth, the company diligently adheres to evolving regulatory standards, enhancing operational resilience and fostering trust among global regulatory bodies. “Our recent foray into cancer medication production, approved by prestigious institutions like Medanta and Tata Memorial, marks a significant milestone in our commitment to innovation and compliance”, highlights Arvind.

The company has been readily investing in talent and technology to be constantly prepared for regulatory changes and challenges and, in turn, sustain leadership in the competitive pharmaceutical landscape. With a steadfast focus on quality, innovation, and client satisfaction, Arvincare is poised for growth, continuing to set benchmarks in pharmaceutical contract manufacturing and reinforcing India's status as a global pharmaceutical powerhouse.